Osteoporosis is a commonly observed bone disease that weakens bone and further enhance the risk of bone breaking. This condition makes bone fragile thus increasing the susceptibility of fracture. According to International Osteoporosis Foundation, osteoporosis causes more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds.
A peptic ulcer is forms of painful sores that develops on the mucosal lining of the stomach, small intestine or lower esophagus. Increase in prevalence of H. Pylori infection, improved diagnostic techniques, easy availability of treatment medication, preferable use of peptic ulcer medication over surgery, increase in rate of smocking and over use of NSAIDs are driving the growth of peptic ulcer drugs market globally.
Amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease is a neurological disease that causes death of nerve cells that control voluntary muscles. Factors such, increase in incidence of ALS, strong pipeline molecule, favorable reimbursement policies in some countries and expected launch of newer medication would drive the growth of ALS treatment market globally.
This report on global multiple drug resistance bacterial infection treatment market studies various vectors and drug class. Rising prevalence of antimicrobial drug resistance and increasing demand for rapid diagnostic testing kits will propel the multiple drug resistance bacterial infection treatment market growth. The limiting factors related to this market are the complex regulatory approvals for the antibiotics which varies according to countries.
This report on global tuberculosis treatment market studies various drug class. According to World Health Organization (WHO) approximately 49 million lives were saved from 2000-2015 through effective diagnosis and treatment, its end TB strategy aims to eradicate the global TB epidemic with 95% reduction in TB deaths, and to cut new cases by 90% from 2015 to 2035 and to ensure that patients are not burdened with huge expenses incurred due to TB.
Cartilage is smooth elastic tissue that protects the ends of bones at the joints by preventing friction between the bones. Factors such as growing incidence of sports injuries, increase in prevalence of bone disorders, rising geriatric and obese population are prime factors that driving the growth of cartilage repair regeneration market globally.
Chemotherapy induced neutropenia is a very common side effect of cancer chemotherapy, it is treated on the basis of etiology, severity, and duration of the neutropenia. Growing prevalence of different forms of cancer and increasing research and development activities for novel therapeutics are primarily driving the growth of chemotherapy induced neutropenia market globally.
Phototherapy refers to the use of light to treat medical conditions. Phototherapy incorporates the use of ultraviolet rays, particularly UVA and UVB wavelength. Broadband UVB, narrowband UVB and PUVA (Psoralen + UVA) are the major UV forms used in phototherapy. UVB is used to treat skin diseases such as atopic eczema, psoriasis, vitiligo, generalised itching and other skin conditions.
Post-Traumatic Stress Disorder Therapeutics Market is expected to grow at a compound annual growth rate of 5% for the forecast period of 2021 to 2029. The increase has been primarily due to increase in violence incidents, accidents and occupational hazards. This report covers all the quantitative aspects of the Post- Traumatic Stress Disorder Therapeutics marketand also talks about its key drivers, the challenges it faces, the growth opportunities present in the market, and its future prospects.
The global allergy diagnosis market is developing significantly with an expected CAGR of above 7.5% from 2019 - 2029. Advances in technological processes are the key growth factor. Skin prick test (SPT) has been highly recommended by European doctors as it is more accurate & least expensive., Introduction of various kinds of kits and instruments have simplified the process of skin prick test (SPT) in the recent years., This led to increase in the revenues and created significant market opportunities.
The drugs by therapeutic area include therapy for oncology, cardiovascular, central nervous system, infectious diseases, respiratory, and others. The therapeutic area represents the specific area of medicine where the drug is intended to be used, based on its mechanism of action and intended clinical use. One of the primary drivers of the drugs by therapeutic area market is the increasing prevalence of diseases worldwide. Chronic diseases such as cancer, cardiovascular diseases, and neurological disorders are a significant burden on healthcare systems globally. There is an urgent need for new and effective therapies to treat these diseases, which has led to the growth of the drugs in the therapeutic area market.
The revenues generated by the drugs in the therapeutic area market have been consistently high over the years. The global pharmaceutical market is expected to reach USD 1.5 trillion by 2023, with oncology being the leading therapeutic area. The increasing demand for new therapies, coupled with advancements in technology and an increasing focus on personalized medicine, is expected to drive the growth of the market in the coming years. One of the emerging trends in the drugs by therapeutic area market is the increasing use of precision medicine. Precision medicine involves tailoring medical treatments to individual patients based on their unique genetic and molecular profiles. The development of precision medicine requires the use of advanced diagnostic tools and drug discovery technologies, which have contributed to the growth of drugs in the therapeutic area market.
Another trend in the drugs by therapeutic area market is the increasing focus on biologics. Biologics are drugs that are produced from living cells and are used to treat a wide range of diseases, including cancer and autoimmune disorders. Biologics are more complex than traditional small-molecule drugs, and their development requires specialized manufacturing processes and clinical trial design. The increasing demand for biologics has contributed to the growth of the drugs by therapeutic area market. The increasing focus on rare diseases is also driving the growth of the drugs by therapeutic area market. Rare diseases are defined as diseases that affect fewer than 200,000 people in the United States. Although each rare disease affects a small number of people, there are over 7,000 rare diseases, which together affect millions of people worldwide. There is an urgent need for new therapies to treat rare diseases, which has led to the growth of drugs in the therapeutic area market.
The increasing use of combination therapies is driving the growth of the drugs by therapeutic area market. Combination therapies involve the use of two or more drugs to treat a disease. Combination therapies can improve patient outcomes by targeting multiple pathways involved in the disease process. The development of combination therapies requires the use of advanced drug discovery technologies and clinical trial design, which has contributed to the growth of the drugs by therapeutic area market. The increasing prevalence of diseases worldwide, advancements in technology, and the emerging trends in precision medicine, biologics, rare diseases, and combination therapies are expected to drive the growth of the drugs by therapeutic area market.